Atea Pharmaceuticals (AVIR) Enterprise Value (2020 - 2022)
Historic Enterprise Value for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to -$665.0 million.
- Atea Pharmaceuticals' Enterprise Value rose 2080.43% to -$665.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$665.0 million, marking a year-over-year increase of 2080.43%. This contributed to the annual value of -$764.4 million for FY2021, which is 1008.59% up from last year.
- Latest data reveals that Atea Pharmaceuticals reported Enterprise Value of -$665.0 million as of Q3 2022, which was up 2080.43% from -$684.5 million recorded in Q2 2022.
- Atea Pharmaceuticals' Enterprise Value's 5-year high stood at -$17.1 million during Q1 2020, with a 5-year trough of -$850.1 million in Q4 2020.
- In the last 3 years, Atea Pharmaceuticals' Enterprise Value had a median value of -$705.5 million in 2022 and averaged -$581.6 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 476237.24% in 2021, then soared by 2080.43% in 2022.
- Over the past 3 years, Atea Pharmaceuticals' Enterprise Value (Quarter) stood at -$850.1 million in 2020, then grew by 10.09% to -$764.4 million in 2021, then grew by 13.0% to -$665.0 million in 2022.
- Its Enterprise Value was -$665.0 million in Q3 2022, compared to -$684.5 million in Q2 2022 and -$705.5 million in Q1 2022.